Brief: Taisho Pharmaceutical - Received Regulatory Approval In Japan To Manufacture And Sell Obesity Drug Alli
Feb 17 (Reuters) - Taisho Pharmaceutical Holdings Co Ltd
4581.T :
* TAISHO PHARMACEUTICAL - RECEIVED REGULATORY APPROVAL IN
JAPAN TO
MANUFACTURE AND SELL OBESITY DRUG ALLI
Source text for Eikon: ID:
Further company coverage: 4581.T
(Reporting by Rocky Swift)
((rocky.swift@thomsonreuters.com;))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10